meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs BSC
vs no additional treatment
vs no control (uncontrolled study)
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
avelumab alone
title
BSC
title
JAVELIN Bladder 100 (all population), 2020 NCT02603432 mUC - M - all population 350/350
JAVELIN Bladder 100 (PDL1>25%), 2020 NCT02603432 mUC - M - PDL1 positive 189/169
Pathology:
mUC - M - all population;
mUC - M - PDL1 positive;
mUC - M - all population
mUC - M - PDL1 positive
JAVELIN Bladder 100 (all population), 2020
JAVELIN Bladder 100 (PDL1>25%), 2020
avelumab alone
2
T1
T1
BSC
0
T0
T0